Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Otonomy stock | $4.83

Own Otonomy stock in just a few minutes.

Fact checked

Otonomy, Inc is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the NASDAQ and all prices are listed in US Dollars. Otonomy employs 49 staff and has a trailing 12-month revenue of around USD$313,000.

How to buy shares in Otonomy

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Otonomy. Find the stock by name or ticker symbol: OTIC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Otonomy reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.83, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Otonomy, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Otonomy. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Otonomy share price

Use our graph to track the performance of OTIC stocks over time.

Otonomy shares at a glance

Information last updated 2020-12-02.
Latest market closeUSD$4.83
52-week rangeUSD$1.53 - USD$4.92
50-day moving average USD$3.9723
200-day moving average USD$3.6907
Wall St. target priceUSD$10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.601

Buy Otonomy shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Otonomy stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Otonomy price performance over time

Historical closes compared with the close of $4.83 from 2020-12-09

1 week (2021-01-07) -20.30%
1 month (2020-12-16) -13.29%
3 months (2020-10-15) 31.25%
6 months (2020-07-15) 13.11%
1 year (2020-01-15) 36.44%
2 years (2019-01-15) 139.11%
3 years (2018-01-13) N/A
5 years (2016-01-15) 17.07

Otonomy financials

Revenue TTM USD$313,000
Gross profit TTM USD$-312,000
Return on assets TTM -26.55%
Return on equity TTM -71.59%
Profit margin 0%
Book value $1.558
Market capitalisation USD$231 million

TTM: trailing 12 months

Shorting Otonomy shares

There are currently 601,472 Otonomy shares held short by investors – that's known as Otonomy's "short interest". This figure is 3.1% down from 620,893 last month.

There are a few different ways that this level of interest in shorting Otonomy shares can be evaluated.

Otonomy's "short interest ratio" (SIR)

Otonomy's "short interest ratio" (SIR) is the quantity of Otonomy shares currently shorted divided by the average quantity of Otonomy shares traded daily (recently around 170872.72727273). Otonomy's SIR currently stands at 3.52. In other words for every 100,000 Otonomy shares traded daily on the market, roughly 3520 shares are currently held short.

However Otonomy's short interest can also be evaluated against the total number of Otonomy shares, or, against the total number of tradable Otonomy shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Otonomy's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Otonomy shares in existence, roughly 10 shares are currently held short) or 0.0131% of the tradable shares (for every 100,000 tradable Otonomy shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Otonomy.

Find out more about how you can short Otonomy stock.

Otonomy share dividends

We're not expecting Otonomy to pay a dividend over the next 12 months.

Otonomy share price volatility

Over the last 12 months, Otonomy's shares have ranged in value from as little as $1.53 up to $4.92. A popular way to gauge a stock's volatility is its "beta".

OTIC.US volatility(beta: 2.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Otonomy's is 2.1573. This would suggest that Otonomy's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Otonomy overview

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site